GT Biopharma (GTBP) had the best year between 2011 and 2020 by a US stock in 2012, returning 3,044,698,370%.

ASSET	YEAR	% RETURN
Ascent Solar Technologies, Inc Common Stock (ASTI)	2011	29,069,667.44%
Versus Systems Inc. (VS)	2011	1,473%
InnovAge (INNV)	2011	2,566.67%
Sequans Communications (SQNS)	2011	3,349,297.59%
Castellum (CTM)	2011	6,521,639.13%
GT Biopharma (GTBP)	2012	3,044,698,370%
QXO (QXO)	2012	8,064,250%
Xcel Brands (XELB)	2012	1,249,900%
Avita Medical (RCEL)	2012	3,124,900%
Cenntro Electric (CENN)	2012	114,285,614.27%
Rezolute (RZLT)	2013	183,291%
Prairie Operating Co Common Stock (PROP)	2013	108,208.47%
Aurinia Pharmaceuticals (AUPH)	2013	5,088.91%
Nutex Health (NUTX)	2013	749,900.7%
Akari Therapeutics (AKTX)	2013	5,580%
Processa Pharmaceuticals (PCSA)	2014	1,796,566.67%
Akari Therapeutics (AKTX)	2014	2,704,125.35%
TCTM Kids IT Education (VSA)	2014	83,093,112.5%
Benitec Biopharma Ltd ADR (BNTC)	2014	72,037.53%
Aurora Cannabis (ACB)	2014	1,403,950.67%
Ascent Solar Technologies, Inc Common Stock (ASTI)	2015	91,743,019.26%
OrganiGram (OGI)	2015	8,150%
GT Biopharma (GTBP)	2015	9,042.86%
Eastside Distilling (BLNE)	2015	7,995.95%
LM Funding America (LMFA)	2015	8,979,697.98%